The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity

• Published in: Molecular cancer therapeutics Vol. 5; no. 7; pp. 1800 - 1806
• Main Authors: Oguri, Tetsuya, Achiwa, Hiroyuki, Sato, Shigeki, Bessho, Yuji, Takano, Yuko, Miyazaki, Mikinori, Muramatsu, Hideki, Maeda, Hiroyoshi, Niimi, Takashi, Ueda, Ryuzo
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 01.07.2006
• Subjects: ABCC5; Antimetabolites, Antineoplastic - pharmacology; Antimetabolites, Antineoplastic - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Cell Line, Tumor; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; deoxycytidine kinase; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - genetics; gemcitabine; Gene Expression; Glutamates - pharmacology; Guanine - analogs & derivatives; Guanine - pharmacology; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Multidrug Resistance-Associated Proteins - antagonists & inhibitors; Multidrug Resistance-Associated Proteins - genetics; Multidrug Resistance-Associated Proteins - metabolism; non–small cell lung cancer; Pemetrexed; Phosphodiesterase Inhibitors - pharmacology; Purinones - pharmacology; ribonucleotide reductase; RNA, Small Interfering - genetics; RNA, Small Interfering - pharmacology; Tumor Suppressor Proteins - antagonists & inhibitors; Tumor Suppressor Proteins - genetics
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.MCT-06-0025

We examined the expression levels of the multidrug resistance protein 5 ( ABCC5 ) gene in non–small cell lung cancer (NSCLC) cell lines to clarify the relationship with the sensitivity to gemcitabine. The expression levels of ABCC5 were inversely correlated with gemcitabine sensitivity significantly ( r = 0.628; P < 0.01) in 17 NSCLC cells, whereas the expression of ABCC5 in the gemcitabine-resistant NSCLC cell line H23/GEM-R was the same as that in parental NCI-H23 cells. Treatment with the ABCC5 inhibitor zaprinast altered the sensitivity to gemcitabine in ABCC5-expressing NSCLC cells. In addition, decreasing the expression of ABCC5 by small interfering RNA altered the cytotoxicity to gemcitabine. These results indicate that modulation of ABCC5 activity could be used to increase the gemcitabine sensitivity in NSCLC. Previously, we found a decreased expression of deoxycytidine kinase in H23/GEM-R cells, and further investigation in this study showed an increased expression of ribonucleotide reductase subunit 1 in H23/GEM-R cells. We therefore also examined the effect of modifying the expression of both genes on gemcitabine resistance. We found that using small interfering RNA to decrease the expression of ribonucleotide reductase subunit 1 resulted in a decreased resistance to gemcitabine in H23/GEM-R cells. Furthermore, pretreatment with pemetrexed resulted in an increased deoxycytidine kinase expression concomitant with the alteration of the resistance to gemcitabine in H23/GEM-R cells. The determinants for sensitivity and the acquired resistance in gemcitabine are quite different; nonetheless, modification of these factors may increase the efficacy of gemcitabine in the treatment of NSCLC. [Mol Cancer Ther 2006;5(7):1800–6]